<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>a2101515zex-10_1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>

</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#03SAN1021_2">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="ma1021_exhibit_10.1"> </A>
<A NAME="toc_ma1021_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit 10.1    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ma1021_employment_agreement"> </A>
<A NAME="toc_ma1021_2"> </A>
<BR></FONT><FONT SIZE=2><B>EMPLOYMENT AGREEMENT    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EMPLOYMENT AGREEMENT made as of the 15th day of November, 2002 between Maxim Pharmaceuticals,&nbsp;Inc. ("Company") and Larry G. Stambaugh ("Executive"). </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>Preliminary Statement  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Company wishes to retain the Executive as Chairman of the Board of Directors, President and Chief Executive Officer of the Company, and the Executive
wishes to continue in such positions, all on the terms and conditions set forth in this Agreement; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW,
THEREFORE, in consideration of the premises, and for other good and valuable consideration, the Company and the Executive agree as follows: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.&nbsp;&nbsp;&nbsp;&nbsp;Term of Agreement.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall commence on October&nbsp;1, 2002 and shall continue in effect until
terminated pursuant to Section&nbsp;5 hereof. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>2.&nbsp;&nbsp;&nbsp;&nbsp;Position and Duties.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as may otherwise be agreed upon between the Company and the Executive, the
Company agrees to employ the Executive, and the Executive agrees to serve the Company, as Chairman of the Board of Directors, President and Chief Executive Officer. The Executive shall render such
services to the Company as are customary for such positions and perform all other services incident thereto. At all times, the Executive shall report directly to the Board of Directors of the Company.
The Executive shall devote substantially all of his working time and efforts to the business and affairs of the Company, except for time spent for service on the boards of directors of other
corporations, vacations as defined by Company policy and civic and charitable activities, and shall represent the Company within its industry. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>3.&nbsp;&nbsp;&nbsp;&nbsp;Place of Performance.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In connection with his employment by the Company, the Executive shall, except as the
Executive may otherwise agree, perform his principal activities at the offices of the Company located in San Diego, California, subject to travel reasonably required for the Company's business. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.&nbsp;&nbsp;&nbsp;&nbsp;Compensation and Related Matters.  </B></FONT></P>

<UL>

<P><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1&nbsp;&nbsp;&nbsp;&nbsp;Base Salary.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;During the Term, the Company shall pay to the Executive, in approximately equal installments
not less often than twice
per month, a base salary of not less than $425,000 per year and such base salary shall be subject to increase, but not reduction, from time to time based upon recommendations from the Compensation
Committee to the Board of Directors. All amounts payable to the Executive pursuant to this Agreement shall be paid subject to such reporting and withholding requirements, if any, as may be imposed by
applicable law and applicable Company policy. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.2&nbsp;&nbsp;&nbsp;&nbsp;Incentive Plan.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Executive shall be eligible to receive bonus payments pursuant to a plan to be prepared
by the Company's Board of Directors with the Executive's participation ("Bonus Plan"). The Bonus Plan shall provide that, assuming reasonable satisfaction of the performance criteria to be set forth
in the Bonus Plan, the Executive shall be eligible to earn an annual bonus with respect to each of the Company's fiscal years during the Term in an amount up to 35% of the Executive's annualized base
salary hereunder, such bonus to be payable within ninety days after the end of each such fiscal year. The bonus will be based upon the annualized base salary for the year in which the bonus applies. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.3&nbsp;&nbsp;&nbsp;&nbsp;Benefit Plans and Arrangement.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Executive shall be entitled to participate in and receive benefits under
the Company's employee benefit plans and arrangements in effect during the Term. The Company shall pay the entire cost of the Executive's health, life and disability insurance coverage under the
Company's plans and policies during the Term, notwithstanding anything to the contrary in such plans and policies. </FONT></P>

</UL>
<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2101515",CP="MAXIM PHARMACEUTICALS, INC.",DN="2",CHK=979894,FOLIO='blank',FILE='DISK018:[03SAN1.03SAN1021]MA1021A.;12',USER='JHILL',CD=';7-FEB-2003;14:30' -->
<A NAME="page_ma1021_1_2"> </A>
<UL>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.4&nbsp;&nbsp;&nbsp;&nbsp;Perquisites.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;During the Term, the Executive shall be entitled to receive fringe benefits ordinarily and
customarily provided by the Company to its senior officers. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.5&nbsp;&nbsp;&nbsp;&nbsp;Expenses.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company shall promptly reimburse the Executive for all normal
out-of-pocket expenses related to the Company's business actually paid or incurred by him in the performance of his services under this Agreement. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.&nbsp;&nbsp;&nbsp;&nbsp;Termination.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Executive's employment hereunder may be terminated under the following circumstances
(without impairing the Executive's rights under benefit plans and arrangements and the Company's policies and procedures): </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.1&nbsp;&nbsp;&nbsp;&nbsp;Termination Upon Death or Permanent Disability.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Term shall automatically terminate in the event of the
death or permanent disability of Executive. For purposes of this Agreement, "permanent disability" shall mean the inability to perform services hereunder for a period of six consecutive months. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.2&nbsp;&nbsp;&nbsp;&nbsp;Termination by Company for Cause.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have the option to terminate the Term (a)&nbsp;for
cause in the event the Executive engages in grossly negligent conduct or willful misconduct in connection with the execution of his duties hereunder which materially and adversely affects the Company,
after written notice by the Company to the Executive of the specific acts that form the basis for the termination, and (b)&nbsp;for the Executive's material nonperformance of his duties hereunder,
provided the nonperformance continues uncorrected for a period of thirty days after written notice thereof by the Company to the Executive specifically identifying the manner in which the Company
believes the Executive has not performed his duties. For purposes of this Section&nbsp;5.2, no act, or failure to act, on the Executive's part shall be considered "willful" unless done, or omitted
to be done, by him not in good faith and without reasonable belief that his act or omission was in the best interests of the Company. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.3&nbsp;&nbsp;&nbsp;&nbsp;Severance.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If the Company terminates Executive's employment other than for cause pursuant to
Section&nbsp;5.2, Executive, in lieu of all other remedies and as liquidated damages, shall be entitled to receive continuation of his then annual base salary plus health care insurance coverage for
a period of three (3)&nbsp;years from said date of termination, with such base salary continuation to be at the rate set forth in section&nbsp;4.1 or, if greater, the rate of the Executive's
current base salary at the date of termination. </FONT></P>

</UL>

<P><FONT SIZE=2>Nothing
herein shall derogate from the Executive's rights under employee benefit plans, programs and arrangements or under applicable law. </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.4&nbsp;&nbsp;&nbsp;&nbsp;Constructive Discharge.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Any significant reduction or adverse change in the nature or scope of the
Executive's authority, duties, status or position contemplated by Section&nbsp;2 hereof, including an involuntary relocation, or a reduction the base salary and/or benefits of the Executive from
those provided for in Section&nbsp;4 hereof as they may from time to time be in effect, will be the basis for the Executive's termination of this Agreement by giving at least 30&nbsp;days prior
notice to the Company and in such event the termination will be treated as a termination by the Company without cause under Section&nbsp;5.3. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.5&nbsp;&nbsp;&nbsp;&nbsp;Benefits Upon Termination for Cause or Voluntary Termination by Executive.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event the Company properly
terminates Executive's employment under this Agreement for cause pursuant to Section&nbsp;5.2 or Executive voluntary resigns from his employment during the Term: </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>a.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2>all salary shall be prorated as of the date of termination and such prorated amount shall be paid to Executive; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>b.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2>all stock options or stock appreciation rights granted to Executive shall be governed by the instruments granting such
rights; and </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2101515",CP="MAXIM PHARMACEUTICALS, INC.",DN="2",CHK=31063,FOLIO='2',FILE='DISK018:[03SAN1.03SAN1021]MA1021A.;12',USER='JHILL',CD=';7-FEB-2003;14:30' -->
<A NAME="page_ma1021_1_3"> </A>
<UL>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>c.&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT SIZE=2>the Company shall (i)&nbsp;make such other and further payment to Executive, his designated beneficiaries and his
dependents as may be provided pursuant to the terms of any employee benefit plan and other compensation plans, programs and structures, or fringe benefit programs in which Executive is a participant
at the time of the termination of his employment with the Company and (ii)&nbsp;promptly reimburse the Executive for any then unreimbursed out-of-pocket expenses pursuant to
Section&nbsp;4.6. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>6.&nbsp;&nbsp;&nbsp;&nbsp;Attorneys Fees.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If litigation shall be instituted to enforce or interpret any provision hereof the prevailing
party will reimburse the other part for his reasonable attorneys' fees and disbursements incurred in such proceeding and will pay prejudgment interest at the legal rate then in effect on any money
judgment or award obtained in such proceeding. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>7.&nbsp;&nbsp;&nbsp;&nbsp;Notice.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;For the purposes of this Agreement, notices, demands and all other communications provided for in the
Agreement shall be in writing and shall be deemed to have been duly given when delivered or mailed by United States registered mail, return receipt requested, postage prepaid, addressed as follows: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="21%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="76%"><FONT SIZE=2>If to the Executive:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="21%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%"><FONT SIZE=2><BR>
Larry G. Stambaugh<BR>
Maxim Pharmaceuticals<BR>
8899 University Center Lane, Suite 400<BR>
San Diego, California 92122</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="21%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%"><FONT SIZE=2><BR>
If to the Company:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="21%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%"><FONT SIZE=2><BR>
Maxim Pharmaceuticals,&nbsp;Inc.<BR>
8899 University Center Lane, Suite 400<BR>
San Diego, California 92122<BR>
Attn: Corporate Secretary</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>or
to such other address as either party may have furnished to the other in writing in accordance herewith, except that notices of change in address shall be effective only upon receipt. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>8.&nbsp;&nbsp;&nbsp;&nbsp;Miscellaneous.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No provisions of this Agreement may be modified, waived or discharged unless such waiver,
modification or discharge is agreed to in writing signed by the Executive and the Company. No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with,
any condition provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provision or conditions at the same or at any proper or subsequent time.
No agreements or representations, oral otherwise, expressed or implied, with respect to the subject matter hereof have been made by either party which are not set forth expressly or referred to in
this Agreement. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of California relating to contracts to be performed entirely
therein. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>9.&nbsp;&nbsp;&nbsp;&nbsp;Validity.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The invalidity or unenforceability of any provision or provisions of this Agreement shall not
affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>10.&nbsp;&nbsp;&nbsp;&nbsp;Headings.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The headings of the paragraphs herein are for convenience only and shall have no significance in
the interpretation of this Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>11.&nbsp;&nbsp;&nbsp;&nbsp;Bind and Inure.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall be binding upon and inure to the benefit of the parties hereto and
their heirs, personal representatives and successors, including any successor of the Company by reason of any dissolution, merger, consolidation, sale of assets or other reorganization of the Company. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=3,EFW="2101515",CP="MAXIM PHARMACEUTICALS, INC.",DN="2",CHK=706426,FOLIO='3',FILE='DISK018:[03SAN1.03SAN1021]MA1021A.;12',USER='JHILL',CD=';7-FEB-2003;14:30' -->
<A NAME="page_ma1021_1_4"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>12.&nbsp;&nbsp;&nbsp;&nbsp;Counterparts.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement may be executed in one or more counterparts, each of which shall be deemed to
be an original but all of which together will constitute one and the same instrument. </FONT></P>

<P><FONT SIZE=2>IN
WITNESS WHEREOF, the Company has caused this Agreement to be executed and its seal to be affixed hereunto by its officer thereunto duly authorized, and Executive has signed this Agreement, as of
the day and year first above written. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="39%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><B>MAXIM PHARMACEUTICALS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="39%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="52%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>ANTHONY E. ALTIG</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Anthony E. Altig<BR>
Vice President, Finance, Chief Financial Officer and Corporate Secretary</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="39%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2><BR>
Date:</FONT></TD>
<TD WIDTH="52%"><FONT SIZE=2><BR>
November&nbsp;15, 2002</FONT><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="42%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="58%"><FONT SIZE=2>/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>LARRY G. STAMBAUGH</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Executive</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=4,EFW="2101515",CP="MAXIM PHARMACEUTICALS, INC.",DN="2",CHK=935313,FOLIO='4',FILE='DISK018:[03SAN1.03SAN1021]MA1021A.;12',USER='JHILL',CD=';7-FEB-2003;14:30' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="03SAN1021_2">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_ma1021_1">Exhibit 10.1</A></FONT><BR>
</UL>
<FONT SIZE=2><A HREF="#toc_ma1021_2">EMPLOYMENT AGREEMENT</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=SFLORES,SEQ=,EFW="2101515",CP="MAXIM PHARMACEUTICALS, INC.",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
